ReviewBiochimie
The role of type I interferon production by dendritic cells in host defense.
Review in Biochimie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 175 citations in OpenAlex.
- Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.Cancer discovery · 2021Trial
- Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets.Science translational medicine · 2017Trial
- BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells.European journal of immunology · 2015Trial
- How age and sex interaction is associated with immune aging with implications for vaccines and age-related autoimmunity.npj aging · 2026Review
- Immune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.Veterinary sciences · 2025Review
- IRF8 Drives Conventional Type 1 Dendritic Cell Differentiation and CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Metabolic deficiencies underlie reduced plasmacytoid dendritic cell IFN-I production following viral infection.Nature communications · 2025Article
- Extracellular Cold-Inducible RNA-Binding Protein and Hemorrhagic Shock: Mechanisms and Therapeutics.Biomedicines · 2024Review
- Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nature communications · 2024Article
- Vaccine and antiviral drug promise for preventing post-acute sequelae of COVID-19, and their combination for its treatment.Frontiers in immunology · 2024Article
- The Impact of Innate Components on Viral Pathogenesis in the Neurotropic Coronavirus Encephalomyelitis Mouse Model.Viruses · 2023Review
- Disruption of type I interferon pathway and reduced production of IFN-α by parabens in virus-infected dendritic cells.Genes & genomics · 2023Article
- Effects of an aged tissue niche on the immune potency of dendritic cells using simulated microgravity.npj aging · 2023Article
- Differentially Expressed Tear Proteins in Sjögren's Syndrome Keratoconjunctivitis Sicca.Translational vision science & technology · 2023Article
- Single-tailed heterocyclic carboxamide lipids for macrophage immune-modulation.Biomaterials science · 2023Article
- Review
- Interactions between the NLRP3-Dependent IL-1β and the Type I Interferon Pathways in Human Plasmacytoid Dendritic Cells.International journal of molecular sciences · 2022Article
- Article
- mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy.Pharmaceutics · 2022Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type I interferons (IFN) and dendritic cells (DC) share an overlapping history, with rapidly accumulating evidence for vital roles for both production of type 1 IFN by DC and the interaction of this IFN both with DC and components of the innate and adaptive immune responses. Within the innate immune response, the plasmacytoid DC (pDC) are the "professional" IFN producing cells, expressing specialized toll-like receptors (TLR7 and -9) and high constitutive expression of IRF-7 that allow them to respond to viruses with rapid and extremely robust IFN production; following activation and production of IFN, the pDC subsequently mature into antigen presenting cells that help to shape the adaptive immune response. However, like most cells in the body, the myeloid or conventional DC (mDC or cDC) also produce type I IFNs, albeit typically at a lower level than that observed with pDC, and this IFN is also important in innate and adaptive immunity induced by these classic antigen presenting cells. These two major DC subsets and their IFN products interact both with each other as well as with NK cells, monocytes, T helper cells, T cytotoxic cells, T regulatory cells and B cells to orchestrate the early immune response. This review discusses some of the converging history of DC and IFN as well as mechanisms for IFN induction in DC and the effects of this IFN on the developing immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.